CD43 Expression is an adverse prognostic factor in diffuse large B-cell lymphoma

Clinical Lymphoma and Myeloma

Volumn 9, Issue 2, 2009, Pages 133-137

  Mitrovic, Zdravko ^a   Ilic, Ivana ^a   Nola, Marin ^a   Aurer, Igor ^a   Sonicki, Zdenko ^a   Basic Kinda, Sandra ^a   Radman, Ivo ^a   Ajdukovic, Radmila ^b   Labar, Boris ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University of Zagreb   (Croatia)

Author keywords

Cyclophosphamide; Doxorubicin; Germinal center; International Prognostic Index; Rituximab; Vincristine

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LEUKOSIALIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; RISK FACTOR; BIOSYNTHESIS; LARGE CELL LYMPHOMA; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD43; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 67650650999     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.033     Document Type: Article

References (37)

1. Remold-O'Donnell E, Zimmerman C, Kenney D, et al. Expression on blood cells of sialophorin, the surface glycoprotein that is defective in Wiskott-Aldrich syndrome. Blood 1987; 70:104-9.
2. Shimizu Y, Shaw S. Cell adhesion: mucins in the mainstream. Nature 1993; 366:630-1.
3. Wong RC, Remold-O'Donnell E, Vercelli D, et al. Signal transduction via leukocyte antigen CD43 (sialophorin). Feedback regulation by protein kinase C. J Immunol 1990; 144:1455-60.
4. Pedraza-Alva G, Merida LB, Burakoff SJ, et al. CD43-specific activation of T-cells induces association of CD43 to Fyn kinase. J Biol Chem 1996; 271:27564-8.
5. Mody PD, Cannon JL, Bankuwala HS, et al. Signalling through CD43 regulates CD4 T-cell trafficking. Blood 2007; 110:2974-82.
6. Ardman B, Sikorski MA, Staunton DE. CD43 interferes with T-lymphocyte adhesion. Proc Natl Acad Sci USA 1992; 89:5001-5.
7. Manjunath N, Correa M, Ardman M, et al. Negative regulation of T-cell adhesion and activation by CD43. Nature 1995; 377:535-8.
8. Matsumoto M, Shigeta A, Furukawa Y, et al. CD43 collaborates with P-selectin glycoprotein ligand-1 to mediate E-selectin-dependent T cell migration into inflamed skin. J Immunol 2007; 178:2499-506.
9. Fuhlbrigge RC, King SL, Sackstein R, et al. CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006; 107:1421-6.
10. Hernandez JD, Nguyen JT, He J, et al. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol 2006; 177:5328-36.
11. He YW, Bevan MJ. High level expression of CD43 inhibits T cell receptor/CD3-mediated apoptosis. J Exp Med 1999; 190:1903-8.
12. Tsao L, Colovai AI, Jiang JG, et al. Characterizing CD43 expression in haematogones using multicolor flow cytometric analysis. Br J Haematol 2005; 128:820-3.
13. Arends JE, Bot FJ, Gisbertz IA, et al. Expression of CD10, CD75 and CD43 in MALT lymphoma and their usefulness in discriminating MALT lymphoma from follicular lymphoma and chronic gastritis. Histopathology 1999; 35:209-15.
14. Lee PS, Beneck D, Weisberger J, et al. Coexpression of CD43 by benign B cells in the terminal ileum. Appl Immunohistochem Mol Morphol 2005; 13:138-41.
15. Knowles DM. Immunophenotypic markers useful in the diagnosis and classification of hematopoietic neoplasma. In: Knowles DM, ed. Neoplastic Hematopathology. 2nd ed. Philadelphia, PA: Lipincott, Wiliams & Wilkins; 2001:93-226.
16. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol 1999; 111:488-94.
17. Gelb AB, Rouse RV, Dorfman RF, et al. Detection of immunophenotypic abnormalities in paraffin-embedded B-lineage non-Hodgkin's lymphomas. Am J Clin Pathol 1994; 102:825-34.
18. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-26.
19. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-91.
20. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-hodgkin's lymphoma. N Engl J Med 1993; 329:987-94.
21. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-11.
22. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for large B-cell lymphoma. N Engl J Med 2002; 346:1937-47.
23. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275-82.
24. Nyman H, Adde M, Karjalainen-Linsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109:4930-5.
25. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26:4587-94.
26. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large B-cell lymphomas. N Engl J Med 2008; 359:2313-23.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working group. J Clin Oncol 1999; 17:1244-53.
28. Nola M, Lukenda A, Bollmann M, et al. Outcome and prognostic factors in ocular adnexal lymhoma. Croat Med J 2004; 45:328-32.
29. Kobayashi T, Yamaguchi M, Kim S, et al. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5-diffuse large B-cell lymphomas. Cancer Res 2003; 63:60-6.
30. Nonomura C, Kikuchi J, Kiyokawa N, et al. CD43, but not P-selectin glycoprotein ligand-1, functions as an E-selectin counter-receptor in human pre-B-cell leukemia NALL1. Cancer Res 2008; 68:790-9.
31. Ziprin P, Alkhamesi NA, Ridgway PF, et al. Tumour-expressed CD43 (sialophorin) mediates tumourmesothelial cell adhesion. Biol Chem 2004; 385:755-61.
32. Dragone LL, Barth RK, Sitar KL, et al. Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival. Proc Natl Acad Sci USA 1995; 92:626-30.
33. Misawa Y, Nagaoka H, Kimoto H, et al. CD43 expression in a B cell lymphoma, WEHI 231, reduces susceptibility to G1 arrest and extends survival in culture upon serum depletion. Eur J Immunol 1996; 26:2573-81.
34. Kadaja-Saarepuu L, Laos S, Jaager K, et al. CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-haematopoietic cancer cells lacking the tumor suppressors p53 or ARF. Oncogene 2008; 27:1705-15.
35. Jimi E, Philips RJ, Rincon M, et al. Activation of NF-IB promotes transition of large, CD43+ pre-B cells to small, CD43-pre B-cells. Int Immunol 2005; 17:815-25.
36. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101:4279-84.
37. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26:3629-36.